Patents by Inventor Petra Marcella Françoise Blom

Petra Marcella Françoise Blom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Radiolabeled macrocyclic EGFR inhibitor
    Patent number: 10716869
    Abstract: The present invention relates to 18-Fluor radiolabeled macrocyclic quinazoline compounds, which are suitable as positron emission tomography (PET) tracers for imaging epidermal growth factor receptors (EGFR), and their use in in vivo diagnosis, preclinical and clinical tumour imaging, patient stratification on the basis of mutational status of EGFR, and assessing tumour response to therapeutic treatments. The present invention also describes precursor compounds and methods of preparing the radiotracers. The invention is relevant to any cancer that is influenced or driven by deregulated EGFR, such as, but not limited to, non-small cell lung cancer (NSCLC), pancreatic, hepatocellular, oesophageal, gastric, colorectal, prostate, cervical, renal, ovarian, breast cancers, head and neck squamous cell carcinoma, and malignant glioma.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: July 21, 2020
    Assignee: Oncodesign SA
    Inventors: Jan Marie Cyriel Jozef Hoflack, Cyril Berthet, Petra Marcella Françoise Blom, Johnny Vercouillie, Caroline Robic, Sarah Catoen, Gilles Voit, Jean-Bernard Deloye
  • RADIOLABELED MACROCYCLIC EGFR INHIBITOR
    Publication number: 20190054197
    Abstract: The present invention relates to 18-Fluor radiolabeled macrocyclic quinazoline compounds, which are suitable as positron emission tomography (PET) tracers for imaging epidermal growth factor receptors (EGFR), and their use in in vivo diagnosis, preclinical and clinical tumour imaging, patient stratification on the basis of mutational status of EGFR, and assessing tumour response to therapeutic treatments. The present invention also describes precursor compounds and methods of preparing the radiotracers. The invention is relevant to any cancer that is influenced or driven by deregulated EGFR, such as, but not limited to, non-small cell lung cancer (NSCLC), pancreatic, hepatocellular, oesophageal, gastric, colorectal, prostate, cervical, renal, ovarian, breast cancers, head and neck squamous cell carcinoma, and malignant glioma.
    Type: Application
    Filed: February 28, 2017
    Publication date: February 21, 2019
    Applicant: Oncodesign SA
    Inventors: Jan Marie Cyriel Jozef Hoflack, Cyril Berthet, Petra Marcella Françoise Blom, Johnny Vercouillie, Caroline Robic, Sarah Catoen
  • Macrocyclic salt-inducible kinase inhibitors
    Patent number: 9586975
    Abstract: The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of SIK kinase, more in particular SIK1, SIK2 and/or SIK3 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of SIK-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 7, 2017
    Assignee: ONCODESIGN S.A.
    Inventors: Petra Marcella Francoise Blom, Jan Marie Cyriel Jozef Hoflack, Pascal Andre Rene Benderitter
  • Macrocyclic FLT3 kinase inhibitors
    Patent number: 9370519
    Abstract: The present invention relates to macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of FLT3 (FMS-Related Tyrosine kinase 3). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: June 21, 2016
    Assignee: Oncodesign S.A.
    Inventors: Petra Marcella Francoise Blom, Jan Marie Cyriel Jozef Hoflack
  • MACROCYCLIC SALT-INDUCIBLE KINASE INHIBITORS
    Publication number: 20160024113
    Abstract: The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of SIK kinase, more in particular SIK1, SIK2 and/or SIK3 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of SIK-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Applicant: ONCODESIGN S.A.
    Inventors: Petra Marcella, Francoise BLOM, Jan Marie, Cyriel, Jozef HOFLACK, Pascal Andre, Rene BENDERITTER
  • MACROCYCLIC RIP2 KINASE INHIBITORS
    Publication number: 20160024114
    Abstract: The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of RIP2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Applicant: ONCODESIGN S.A.
    Inventors: Petra Marcella, Francoise Blom, Jan Marie Cyriel Jozef Hoflack, Pascal Andre, Rene Benderitter
  • MACROCYCLIC FLT3 KINASE INHIBITORS
    Publication number: 20150283141
    Abstract: The present invention relates to macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of FLT3 (FMS-Related Tyrosine kinase 3). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer.
    Type: Application
    Filed: June 19, 2015
    Publication date: October 8, 2015
    Inventors: Petra Marcella Francoise Blom, Jan Marie Cyriel Jozef Hoflack
  • Macrocyclic FLT3 kinase inhibitors
    Patent number: 9090630
    Abstract: The present invention relates to macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of FLT3 (FMS-Related Tyrosine kinase 3). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: July 28, 2015
    Assignee: Oncodesign S.A.
    Inventors: Petra Marcella Francoise Blom, Jan Marie Cyriel Jozef Hoflack
  • MACROCYCLIC FLT3 KINASE INHIBITORS
    Publication number: 20140303159
    Abstract: The present invention relates to macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of FLT3 (FMS-Related Tyrosine kinase 3). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer.
    Type: Application
    Filed: September 28, 2012
    Publication date: October 9, 2014
    Inventors: Petra Marcella Francoise Blom, Jan Marie Cyriel Jozef Hoflack